New Advisory for GSK and Pfizer's RSV Vaccines Due to Rare Neurological Disorder Risks

In a newly released advisory, health authorities have notified clinicians and the public about a potential risk associated with the respiratory syncytial virus (RSV) vaccines developed by GSK and Pfizer. These vaccines, which have been hailed as significant advancements in the fight against RSV, are now under scrutiny due to reports revealing a rare neurological disorder potentially linked to their use.

Continue reading